<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02081378</url>
  </required_header>
  <id_info>
    <org_study_id>CABL001X2101</org_study_id>
    <nct_id>NCT02081378</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL</brief_title>
  <official_title>A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The design of a phase I, open label, dose finding study was chosen in order to establish a
      safe and tolerated dose of single agent ABL001 in CML and Ph+ ALL patients who are relapsed
      or refractory to or are intolerant of TKIs, and of ABL001+Nilotinib, ABL001+Imatinib and
      ABL001+Dasatinib in Ph positive CML patients who are relapsed or refractory to TKIs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This first-in-human trial with ABL001 is a dose escalation study whose primary purpose is to
      estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of
      single agent ABL001 in CML or Ph+ ALL patients, and in combination with either Nilotinib or
      Imatinib or Dasatinib in Ph positive CML patients. The safety, tolerability and
      pharmacokinetic (PK) profile of ABL001 and ABL001+Nilotinib, ABL001+Imatinib and
      ABL001+Dasatinib will be assessed together with an evaluation of pharmacodynamic (PD) changes
      in peripheral blood mononuclear cells (PBMC) and bone marrow aspirates and all data may
      contribute to the assessment of the RDE.

      An understanding of the MTD/RDE, safety profile, PK/PD relationship, and preliminary evidence
      of anti-CML and ALL activity will be used to inform future development in adults with CML and
      Ph+ ALL. By virtue of its distinct pharmacological profile and by preclinical pharmacological
      studies demonstrating an additive effect, a combination of ABL001 and a tyrosine-kinase
      inhibitor (TKI) has the potential to achieve a deeper molecular response in a higher
      proportion of CML patients as compared to single agent TKI therapy. Such a combination has
      the added advantage of targeting the ABL kinase domain at two distinct locations,
      theoretically preventing single point mutation-associated treatment resistance. The
      prediction is that a nilotinib+ABL001, imatinib+ABL001 and/or dasatinib+ABL001 combination
      will increase the percentage of patients who achieve a complete molecular response (CMR) and
      decrease the time to CMR, thereby increasing the possibility of achieving sustained
      treatment-free remissions in these patients. In addition, some patients may be intolerant of
      therapy with TKIs or may develop mutations that promote resistance to TKI therapy. In these
      patients, ABL001 may provide a novel therapeutic option.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2014</start_date>
  <completion_date type="Anticipated">December 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs) during the first cycle of study treatment</measure>
    <time_frame>First Cycle is 28 days</time_frame>
    <description>Determine the MTD and/or RDE of ABL001 as single agent in CML and Ph+ ALL, and in combination with either nilotinib or imatinib or dasatinib in CML patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hematologic Response</measure>
    <time_frame>At screening and first day of cycle 2 and 3 and every 12 weeks afterwards</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytogenetic response</measure>
    <time_frame>at screening or when a patient's BCR-ABL ratio has risen to &gt;1%</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BCR-ABL transcript level</measure>
    <time_frame>At screening and first day of cycle 2 and 3 and every 12 weeks afterwards</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of ABL001 as measured in plasma</measure>
    <time_frame>Cycle 1 days 1,2,8,15,16 and 22. Cycle 2 days 1 and 2, and subsequent cycles at the begining of each cycle up to cycle 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin of ABL001 as measured in plasma</measure>
    <time_frame>Cycle 1 days 1,2,8,15,16 and 22. Cycle 2 days 1 and 2, and subsequent cycles at the begining of each cycle up to cycle 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of ABL001 as measured in plasma</measure>
    <time_frame>Cycle 1 days 1,2,8,15,16 and 22. Cycle 2 days 1 and 2, and subsequent cycles at the begining of each cycle up to cycle 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast of ABL001 as measured in plasma</measure>
    <time_frame>Cycle 1 days 1,2,8,15,16 and 22. Cycle 2 days 1 and 2, and subsequent cycles at the begining of each cycle up to cycle 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau of ABL001 as measured in plasma</measure>
    <time_frame>Cycle 1 days 1,2,8,15,16 and 22. Cycle 2 days 1 and 2, and subsequent cycles at the begining of each cycle up to cycle 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of ABL001 as measured in plasma</measure>
    <time_frame>Cycle 1 days 1,2,8,15,16 and 22. Cycle 2 days 1 and 2, and subsequent cycles at the begining of each cycle up to cycle 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Collected from screening visit through post-treatment follow-up period</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>ABL001 in CML patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation study to estimate the MTD and/or RDE of ABL001 in adult patients with CML</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABL001+Nilotinib in CML patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation study to estimate the MTD and/or RDE of ABL001 in combination with Nilotinib in adult CML patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABL001 in Ph+ ALL patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation study to estimate the MTD and/or RDE of ABL001 in adult patients with Ph positive ALL patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABL001+Imatinib in CML patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation study to estimate the MTD and/or RDE of ABL001 in combination with imatinib in adult CML patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABL001+dasatinib in CML patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation study to estimate the MTD and/or RDE of ABL001 in combination with dasatinib in adult CML patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABL001</intervention_name>
    <description>ABL001 will be administered orally in a dose escalation schedule.</description>
    <arm_group_label>ABL001 in CML patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABL001 + Nilotinib</intervention_name>
    <description>ABL001 and Nilotinib will be administered orally in CML patients</description>
    <arm_group_label>ABL001+Nilotinib in CML patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABL001</intervention_name>
    <description>ABL001 will be administered orally in Ph+ ALL patients</description>
    <arm_group_label>ABL001 in Ph+ ALL patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABL001+imatinib</intervention_name>
    <description>ABL001 and imatinib will be administered orally in CML patients</description>
    <arm_group_label>ABL001+Imatinib in CML patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABL001+dasatinib</intervention_name>
    <description>ABL001+dasatinib will be administered orally in CML patients</description>
    <arm_group_label>ABL001+dasatinib in CML patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For CML patients either:

          -  a. Patients with Ph+ CML in chronic or accelerated phase who were previously treated
             with at least two different tyrosine kinase inhibitors prior to study entry and are
             relapsed, refractory to or intolerant of TKIs as determined by investigators or

          -  b. Patients with CML in chronic or accelerated phase who exhibit relapsed disease
             associated with the presence of the T315I &quot;gatekeeper mutation&quot; after at least one TKI
             are also eligible provided that no other effective therapy exists

        For ALL and CML-BP patients:

          -  Patients with CML BP or Ph+ ALL who have a cytopathologically confirmed diagnosis and
             are relapsed or refractory to at least one prior TKI or intolerant of TKIs. TKI
             failure for Ph+ ALL and CML-BP patients is defined as at least the loss of Molecular
             Response (MR) 4.5 (BCR-ABL â‰¤ 0.0032%)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

          -  Willingness and ability to comply with all study procedures

          -  Written informed consent obtained prior to any screening procedures

        Exclusion Criteria:

        Wash-out period:

          -  Systemic antineoplastic therapy (including cytotoxic chemotherapy, alfa-interferon and
             toxin immunoconjugates) or any experimental therapy within 14 days or 5 half-lives,
             whichever is shorter, before the first dose of study treatment

          -  Therapy with TKIs as single agent within 5 half-lives before the first dose of study
             treatment

          -  Unconjugated monoclonal antibody therapies within 28 days or 5 half-lives, whichever
             is shorter, before the first dose of study treatment

          -  For patients receiving ABL001 in combination with either nilotinib or imatinib or
             dasatinib, intolerance to nilotinib, imatinib or dasatinib, respectivelyRadiotherapy
             with a wide field of radiation within 4 weeks or radiotherapy with a limited field of
             radiation for palliation within 1 week of the first dose of study treatment.

          -  CNS irradiation for meningeal leukemia, except if radiotherapy occurred &gt; 3 months
             previously. At least four weeks must have elapsed since prophylactic CNS irradiation
             given as part of a front-line therapy regimen for ALL

          -  Major surgery within 2 weeks before the first dose of study treatment

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>Novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute Hematology / Oncology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Milillo</last_name>
      <phone>617-632-6840</phone>
      <email>shannon_milillo@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel J. DeAngelo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center SC</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0944</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelagh L. Elliott</last_name>
      <phone>734-232-0759</phone>
      <email>shelagh@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Moshe Talpaz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Mauro J. Mauro, MD</last_name>
      <phone>212-639-3107</phone>
      <email>maurom@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Michael J. Mauro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University SC-6</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bianca Gille</last_name>
      <phone>503-494-4603</phone>
      <email>gille@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Michael J. Heinrich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson Cancer Center UT MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge E Cortes, MD</last_name>
      <phone>713-794-5783</phone>
      <email>Jcortes@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Jorge E. Cortes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute SC</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Ernst</last_name>
      <email>aaron.ernst@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Michael W. Deininger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <state>Cedex 10</state>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Seocho-gu</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2014</study_first_submitted>
  <study_first_submitted_qc>March 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2014</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CML</keyword>
  <keyword>Ph+ ALL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

